首页|期刊导航|Cancer Innovation|Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-Tumor

Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-TumorOA

中文摘要

Human epidermal growth factor receptor 2(HER2)is a key biomarker and therapeutic target in several malignancies,including breast,gastric,and other solid tumors.Recent advancements in cancer molecular profiling and the Food and Drug Administration''s approval of trastuzumab deruxtecan for HER2-positive pan-tumor indications have highlighted the broader relevance of HER2 alterations across diverse cancers.However,the lack of standardized guidelines for HER2 testing in a pan-tumor context creates variability in clinical practice,hindering the optimal implementation of HER2-targeted therapies beyond traditional indications.To address this gap,a multidisciplinary panel of Chinese experts has developed a consensus providing comprehensive recommendations on diagnostic strategies,testing methodologies,and clinical applications of HER2 overexpression detection.By establishing a unified framework for HER2 overexpression assessment,this consensus aims to enhance the precision of HER2 testing,optimize patient selection for targeted therapies,and improve clinical outcomes across a wide spectrum of HER2 overexpression malignancies.

Zhe Wang;Lin Chen;Wei Rao;Baoshan Cao;Muyan Cai;Xiangshan Fan;Yuan Ji;Yuan Li;Yan Song;Yan Sun;Yu Sun;Chunyan Wu;Qingxin Xia;Yanfeng Xi;Liyan Xue;Rutie Yin;Han Liang;Jianming Ying

Department of Pathology,Xijing Hospital and School of Basic Medicine,Fourth Military Medical University,Xi''an,ChinaDepartment of Gastrointestinal Surgery,Peking University International Hospital,Beijing,ChinaDepartment of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology and Radiation Sickness,Peking University Third Hospital,Beijing,ChinaDepartment of Pathology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Guangzhou,ChinaDepartment of Pathology,The First Affiliated Hospital of Anhui Medical University,Hefei,ChinaDepartment of Pathology,Zhongshan Hospital,Fudan University,Shanghai,ChinaDepartment of Pathology,Fudan University Shanghai Cancer Center,Shanghai,ChinaDepartment of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Pathology,Tianjin Medical University Cancer Institute&Hospital,Tianjin,ChinaDepartment of Pathology,Peking University Cancer Hospital&Institute,Beijing,ChinaDepartment of Pathology,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai,ChinaDepartment of Pathology,Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou,ChinaDepartment of Pathology,Shanxi Province Cancer Hospital,Taiyuan,ChinaDepartment of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,ChinaDepartment of Obstetrics and Gynecology,West China Second University Hospital,Sichuan University,Chengdu,ChinaDepartment of Gastric Surgery,Tianjin Medical University Cancer Institute&Hospital,Tianjin,ChinaDepartment of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,China

医药卫生

consensushuman epidermal growth factor receptor 2overexpressionpan-tumortesting

《Cancer Innovation》 2026 (2)

P.3-13,11

supported by National High Level Hospital ClinicalResearch Funding.

10.1002/cai2.70060

评论